Hypertonia, COPD és Covid-19. Fókuszban az antihipertenzív terápia

FARSANG, CSABA ✉ [Farsang, Csaba (Vérnyomásszabályo...), author] Department of Pharmacology and Pharmacotherapy (SU / FM / I)

Hungarian Scientific Survey paper (Journal Article)
Published: LEGE ARTIS MEDICINAE 0866-4811 2063-4161 31 (5-6) pp. 193-199 2021
  • SJR Scopus - Medicine (miscellaneous): Q4
Identifiers
Chronic obstructive pulmonary disease is a very common comorbidity of hypertension and it is often unrecognised by physicians. The factors involved in the pathomechanism of both diseases should be realised when choosing treatment. Among factors, hypoxia, increased tone of sympathetic nervous system and activation of reninangiotensin- aldosterone system should primarily be considered. Vascular wall damage and endothelial dysfunction has an important role in both conditions. The goals of treatment are elimination of risk factors, optimizing the blood pressure, the consequential prevention of cardio-cerebrovascular, renal and pulmonary damage; finally prolonging the patients' life and improving their quality of life as well. Both hypertension and COPD significantly worsen the condition of COVID-19 patients since they increase the severity of the disease and the rate of in-patients' and their mortality. In the treatment of hypertension among COPD and COVID-19 patients there must be emphasized the medication inhibiting of renin-angiotensin-aldosterone system, such as angiotensin-converting en - zyme inhibitors or angiotensin-II AT1 re - cep tor antagonists. Special attention concerned the beneficial effect of mineralocorticoid receptor antagonist spironolactone. Other antihypertensive drugs (calcium channel blockers, thiazide-like diu retics, high selectivity β1 receptor antagonists) may supplement the treatment if necessary. Long-acting β2 receptor agonists, muscarinic receptor antagonists and inhalation corticosteroids may be administered in double or triple combination also in hypertension and COPD as well. It is important to note, that statin therapy and also vitamin D3 improve the condition of COVID-19 patients. © 2021 Literatura Medica Publishing House. All rights reserved.
Citation styles: IEEEACMAPAChicagoHarvardCSLCopyPrint
2021-11-29 03:26